Amneal Pharmaceuticals, Inc. Class A AMRX 深 沪
等待开盘 11-06 09:30:00 美东时间
19.45
-0.500
-2.51%
华盛通- 最 高20.48
- 今 开20.04
- 成交量 494.89万股
- 最 低 19.385
- 昨 收 19.95
- 总市值 62.11亿
- 52周最高 21.6811
- 市盈率 静 87.69
- 换手率 1.55%
- 52周最低 11.39
- 委 比 20.62%
- 总股本 3.19亿
- 历史最高 24.48
- 量 比 0.96
- 振 幅 5.49%
- 历史最低 1.24
- 每 手 1
- 风险率 2.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 大摩上调AMD目标价至725美元；安进、多邻国绩后获华尔街大行看多
今日重点评级关注：康托·菲茨杰拉德：维持Supernus"超配"评级，目标价从67美元升至87美元；丰业银行：维持Atlas Energy Solutions"跑赢大市"评级，目标价从17美元升至18美元
11-05 14:06
JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $25
JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $24 to $25.
11-05 03:27
Amneal Pharmaceuticals Q3 2026 Earnings Call Transcript
Amneal Pharmaceuticals (NASDAQ:AMRX) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.be...
11-03 22:19
美股大行评级 | 潜在涨幅109.52%！富国银行上调Helus Pharma目标价至22美元，维持"超配"评级
今日重点评级关注：富国银行：维持Helus Pharma"超配"评级，目标价从16美元升至22美元；美银证券：维持SpaceX"买入"评级，目标价从235美元升至275美元
10-23 12:30
JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24
JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $22 to $24.
10-22 21:40
Oppenheimer's fall 2026 SMID-cap ideas include four Strong Buy stocks
As investors look beyond the largest companies for potential opportunities, Oppenheimer Equity Research has updated its list of SMID-cap ideas for Fall 2026, highlighting a group of companies across t...
10-06 21:09
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
Amneal Announces FDA Approval and Launch of Lanreotide Injection
Amneal Pharmaceuticals announced FDA approval of its lanreotide injection, a long-acting treatment for acromegaly, neuroendocrine tumors, and carcinoid syndrome. The product, referencing SOMATULINE® Depot, received Competitive Generic Therapy (CGT) designation and will launch immediately. With in-house manufacturing, Amneal aims to broaden access and deliver long-term value. U.S. annual sales for SOMATULINE® Depot were $983 million in 2026, per I...
09-18 20:01
美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
Salesforce To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Guggenheim cut the price target for LYFT Inc (NASDAQ:LYFT) from $22 to $16. Guggenheim analyst Taylor Manley d...
09-17 20:50
